128 related articles for article (PubMed ID: 36924995)
1. Exploring temozolomide encapsulated PEGylated liposomes and lyotropic liquid crystals for effective treatment of glioblastoma: in-vitro, cell line, and pharmacokinetic studies.
Waghule T; Laxmi Swetha K; Roy A; Narayan Saha R; Singhvi G
Eur J Pharm Biopharm; 2023 May; 186():18-29. PubMed ID: 36924995
[TBL] [Abstract][Full Text] [Related]
2. Angiopep-2 Grafted PAMAM Dendrimers for the Targeted Delivery of Temozolomide:
Sahoo RK; Kumar H; Jain V; Sinha S; Ajazuddin ; Gupta U
ACS Biomater Sci Eng; 2023 Jul; 9(7):4288-4301. PubMed ID: 37307155
[TBL] [Abstract][Full Text] [Related]
3. Liposomal temozolomide drug delivery using convection enhanced delivery.
Nordling-David MM; Yaffe R; Guez D; Meirow H; Last D; Grad E; Salomon S; Sharabi S; Levi-Kalisman Y; Golomb G; Mardor Y
J Control Release; 2017 Sep; 261():138-146. PubMed ID: 28666727
[TBL] [Abstract][Full Text] [Related]
4. Brain Targeting by Liposome-Biomolecular Corona Boosts Anticancer Efficacy of Temozolomide in Glioblastoma Cells.
Arcella A; Palchetti S; Digiacomo L; Pozzi D; Capriotti AL; Frati L; Oliva MA; Tsaouli G; Rota R; Screpanti I; Mahmoudi M; Caracciolo G
ACS Chem Neurosci; 2018 Dec; 9(12):3166-3174. PubMed ID: 30015470
[TBL] [Abstract][Full Text] [Related]
5. Improving temozolomide biopharmaceutical properties in glioblastoma multiforme (GBM) treatment using GBM-targeting nanocarriers.
Delello Di Filippo L; Hofstätter Azambuja J; Paes Dutra JA; Tavares Luiz M; Lobato Duarte J; Nicoleti LR; Olalla Saad ST; Chorilli M
Eur J Pharm Biopharm; 2021 Nov; 168():76-89. PubMed ID: 34461214
[TBL] [Abstract][Full Text] [Related]
6. Dual-targeting immunoliposomes using angiopep-2 and CD133 antibody for glioblastoma stem cells.
Kim JS; Shin DH; Kim JS
J Control Release; 2018 Jan; 269():245-257. PubMed ID: 29162480
[TBL] [Abstract][Full Text] [Related]
7. Formulation and statistical optimization of intravenous temozolomide-loaded PEGylated liposomes to treat glioblastoma multiforme by three-level factorial design.
Vanza J; Jani P; Pandya N; Tandel H
Drug Dev Ind Pharm; 2018 Jun; 44(6):923-933. PubMed ID: 29280385
[TBL] [Abstract][Full Text] [Related]
8. Efficient delivery of Temozolomide using ultrasmall large-pore silica nanoparticles for glioblastoma.
Janjua TI; Cao Y; Ahmed-Cox A; Raza A; Moniruzzaman M; Akhter DT; Fletcher NL; Kavallaris M; Thurecht KJ; Popat A
J Control Release; 2023 May; 357():161-174. PubMed ID: 36965857
[TBL] [Abstract][Full Text] [Related]
9. Polymeric and small molecule-conjugates of temozolomide as improved therapeutic agents for glioblastoma multiforme.
Jatyan R; Singh P; Sahel DK; Karthik YG; Mittal A; Chitkara D
J Control Release; 2022 Oct; 350():494-513. PubMed ID: 35985493
[TBL] [Abstract][Full Text] [Related]
10. Controlled release of liposome-encapsulated temozolomide for brain tumour treatment by convection-enhanced delivery.
Lin CY; Li RJ; Huang CY; Wei KC; Chen PY
J Drug Target; 2018 Apr; 26(4):325-332. PubMed ID: 28911239
[TBL] [Abstract][Full Text] [Related]
11. Polymer-Temozolomide Conjugates as Therapeutics for Treating Glioblastoma.
Ward SM; Skinner M; Saha B; Emrick T
Mol Pharm; 2018 Nov; 15(11):5263-5276. PubMed ID: 30354145
[TBL] [Abstract][Full Text] [Related]
12. Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.
Verreault M; Wehbe M; Strutt D; Masin D; Anantha M; Walker D; Chu F; Backstrom I; Kalra J; Waterhouse D; Yapp DT; Bally MB
J Control Release; 2015 Dec; 220(Pt A):348-357. PubMed ID: 26528901
[TBL] [Abstract][Full Text] [Related]
13. Encapsulation of Temozolomide in a Calixarene Nanocapsule Improves Its Stability and Enhances Its Therapeutic Efficacy against Glioblastoma.
Renziehausen A; Tsiailanis AD; Perryman R; Stylos EK; Chatzigiannis C; O'Neill K; Crook T; Tzakos AG; Syed N
Mol Cancer Ther; 2019 Sep; 18(9):1497-1505. PubMed ID: 31213505
[TBL] [Abstract][Full Text] [Related]
14. Deleterious impact of a generic temozolomide formulation compared with brand-name product on the kinetic of platelet concentration and survival in newly diagnosed glioblastoma.
Fontanilles M; Fontanilles A; Massy N; Rouvet J; Pereira T; Alexandru C; Hanzen C; Basuyau F; Langlois O; Clatot F; Tennevet I; Di Fiore F; Joannidès R; Lamoureux F
Fundam Clin Pharmacol; 2020 Aug; 34(4):484-494. PubMed ID: 31994757
[TBL] [Abstract][Full Text] [Related]
15. Overcoming blood brain barrier with a dual purpose Temozolomide loaded Lactoferrin nanoparticles for combating glioma (SERP-17-12433).
Kumari S; Ahsan SM; Kumar JM; Kondapi AK; Rao NM
Sci Rep; 2017 Jul; 7(1):6602. PubMed ID: 28747713
[TBL] [Abstract][Full Text] [Related]
16. Focused ultrasound-induced blood-brain barrier opening to enhance temozolomide delivery for glioblastoma treatment: a preclinical study.
Wei KC; Chu PC; Wang HY; Huang CY; Chen PY; Tsai HC; Lu YJ; Lee PY; Tseng IC; Feng LY; Hsu PW; Yen TC; Liu HL
PLoS One; 2013; 8(3):e58995. PubMed ID: 23527068
[TBL] [Abstract][Full Text] [Related]
17. Liposome encapsulated of temozolomide for the treatment of glioma tumor: preparation, characterization and evaluation.
Gao J; Wang Z; Liu H; Wang L; Huang G
Drug Discov Ther; 2015 Jun; 9(3):205-12. PubMed ID: 26193943
[TBL] [Abstract][Full Text] [Related]
18. Good tolerability of maintenance temozolomide in glioblastoma patients after severe hematological toxicity during concomitant radiotherapy and temozolomide treatment: report of two cases.
Lombardi G; Caccese M; Bellu L; Pambuku A; Bergo E; Berti F; Gardiman MP; Della Puppa A; Denaro L; Dal Pos S; Zagonel V
Anticancer Drugs; 2018 Oct; 29(9):924-928. PubMed ID: 30080691
[TBL] [Abstract][Full Text] [Related]
19. Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer.
Shapira-Furman T; Serra R; Gorelick N; Doglioli M; Tagliaferri V; Cecia A; Peters M; Kumar A; Rottenberg Y; Langer R; Brem H; Tyler B; Domb AJ
J Control Release; 2019 Feb; 295():93-101. PubMed ID: 30605703
[TBL] [Abstract][Full Text] [Related]
20. Successful Partnerships: Exploring the Potential of Immunogenic Signals Triggered by TMZ, CX-4945, and Combined Treatment in GL261 Glioblastoma Cells.
Villamañan L; Martínez-Escardó L; Arús C; Yuste VJ; Candiota AP
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33810611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
